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A B S T R A C T
As epidemiological data concerning varicella in Germany were not available, a retrospective study was
conducted to investigate the impact of the disease, focusing also on economic aspects. A representative
German-wide sample of 1334 unvaccinated varicella cases was obtained in 1999 from randomly selected
paediatric (P) and general, as well as internal, mainly adult (A), practices. Following representative
weighting, the median age was 5 years, with 90% of cases aged < 12 years. The highest incidence was in
children aged 5–6 years. Varicella-related complications occurred in 5.7% of patients, and accounted for
0.1 hospital days ⁄ case on average. Certificates of sick leave were issued for 1.3 sick days ⁄ case, with
0.6 days paid by health insurance funds to parents caring for their sick child, and 0.7 days paid by the
employer. With an annual incidence of 760 000 diagnosed cases in Germany for the year 1999, this
amounts to an annual cost of c.150 million Euro, with c. 50 million Euro paid by the statutory health
insurance system. It was concluded that universal varicella vaccination in Germany would provide
essential clinical improvements for patients and prevent hospital admissions. In addition, significant
economic benefits can be expected, mainly because of the high level of indirect health costs in Germany.
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I N T R O D U C T I O N
Varicella (chickenpox) is a highly communicable,
vaccine-preventable disease that, in Germany, is
non-notifiable. While a number of infectious
diseases are controlled and repressed in industr-
ialised countries, varicella incidence is nearly
unchanged in Germany, with 760 000 new cases
in a population of 82 million in 1999 [1]. Official
recommendations for vaccination against varicel-
la in Germany include only seronegative people
at special risk, such as children with leukaemia,
solid tumours or planned immunosuppression, as
well as contacts of such children, medical staff,
seronegative women who wish to become
pregnant, and adolescents without a history of
varicella [2]. In Germany, varicella is commonly
considered to be a benign disease of young
children with a mild course. However, a varicella
vaccine is licensed for routine use in Japan and
Korea, and general vaccination against varicella is
recommended in the United States. The vaccine is
well-tolerated and effective, with an estimated
efficacy of > 90% [3,4].
The World Health Organisation [5] has raised
the possible importance of varicella vaccination
in industrialised countries from a health econo-
mic point of view. Because of the likelihood that
nearly every person will contract varicella at
some time, high indirect costs because of work
loss may result, and economic analyses have
already been carried out for some countries.
Thus, a routine varicella vaccination programme
for children in the USA was shown to be cost-
effective [6] and, based on a cost–benefit analysis,
possible improvements have also been described
for France and Australia [7,8]. Similar results
Corresponding author and reprint requests: S. Wagenpfeil,
Institute for Medical Statistics and Epidemiology, Klinikum
rechts der Isar der TU Mu¨nchen, Ismaninger Strasse 22,
D-81675 Munich, Germany
E-mail: Stefan.Wagenpfeil@imse.med.tu-muenchen.de
 2004 Copyright by the European Society of Clinical Microbiology and Infectious Diseases
justifying a universal vaccination programme for
children aged 15 months have been published for
Spain [9]. An epidemiological study in Italy [10]
also suggested general vaccination of children
aged > 18 months. Beutels et al. [11] attempted to
analyse the benefits and costs of implementing a
routine vaccination programme in Germany, but
the lack of fundamental epidemiological data on
varicella in Germany meant that estimates on
prevalence and hospitalisation rates were adap-
ted from USA studies to the German context, or
were simply subject to expert opinion.
In order to supply the valid epidemiological
data that is fundamental for economic evaluations
of varicella vaccination strategies, the present
study describes a retrospective, German-wide
study. Data collection was focused on the age
distribution, severity of disease course, complica-
tion rates and hospitalisations of diagnosed cases.
Inability to work was assessed for diagnosed
varicella cases, as well as for parents or guardians
caring for an ill child. Certificates of sick leave are
a cost factor in the German health care system, in
particular for varicella. This is in accordance with
other studies in industrialised countries [9,10,12]
that stress the essential role of indirect costs in
economic analyses of varicella. The present study
aimed to provide an overview of the situation
concerning varicella in Germany, as well as
demographic information on sex distribution
and health insurance status [13,14]. The data
obtained should provide a basis for determining
the direct and indirect costs of varicella infection
in Germany.
M A T E R I A L S A N D M E T H O D S
Results and conclusions were based on empirical data from a
German-wide, epidemiological study of 1349 diagnosed var-
icella cases in 1999. Only unvaccinated cases were included in
the analysis; therefore 15 cases were excluded (three were
vaccinated and 12 had an unknown vaccination status).
Data were collected retrospectively from a random sample
of 282 outpatient practices, comprising 231 paediatric (P) and
51 general, as well as internal, mainly adult (A) practices.
Estimates obtained from data either in the (P) or (A) popula-
tion are representative only within the stratum of paediatric
varicella cases or diagnoses from general and internal prac-
tices, respectively. As the ratio of 231:51 may not reflect overall
diagnosed varicella cases, the estimates were weighted
between the (A) and (P) populations according to real
prevalence rates in order to obtain representative results. This
was done by using the German prescription index [1], yielding
a ratio of 60:40 for (P):(A) for the year 1999. Thus, estimates
from the (P) population were multiplied by a factor of 0.6, and
those for the (A) population by 0.4. Adding the two products
yields the overall representative estimates.
The prescription index [1] also allows an estimate of the
incidence of diagnosed varicella cases for Germany, namely
760 000 cases for 1999. With a population of 82 million [15], an
incidence rate was calculated of 9.3 new varicella cases in
Germany ⁄ 1000 inhabitants within a year.
Study design
The data from the sample of 1349 diagnosed varicella cases
were collected cross-sectionally and retrospectively for the
year 1999. Data were obtained anonymously from medical files
via telephone interviews with a representative and German-
wide sample of paediatric, general and internal practices.
Physicians were chosen randomly from an electronic version
of the classified directory (yellow pages) for Germany in two
strata: one sample from listed paediatric practices, resulting in
231 compliant paediatricians; and a second sample from listed
general and internal practices, resulting in 51 compliant
general practitioners and internists acting as family doctors.
For each of the compliant practices, a maximum of five
diagnosed varicella cases was collected randomly. The samp-
ling and evaluation effort took 12 months. It should be noted
that hospitalisation events are commonly known to family
doctors in Germany.
Statistical analysis
The age distribution of diagnosed varicella cases was dis-
played as a histogram with relative and cumulative frequen-
cies, respectively. Mean age and ranges were calculated.
Further results were presented as mean and probability
estimates with respective 95% confidence intervals (CIs). If
necessary, exact 95% CIs were computed for relative frequen-
cies. Point sensitivity analysis with respect to the weighting of
the (A) and (P) populations was also addressed. From sample
size considerations, it was necessary to collect at least 1200
varicella cases (including 7% dropouts) in order to obtain
95% CIs enlarging ± 1% for relative frequency estimates of
3%. The extension of ± 1% was considered to be sufficiently
small.
R E S U L T S
Of 1349 collected varicella cases, 91 were immu-
nocompromised, of which one was vaccinated.
Excluding all the vaccinated cases and patients of
unknown vaccination status, 1334 unvaccinated
varicella cases were available for analysis. Of
these, 50.1% were male, and 92.4% were mem-
bers of a statutory health insurance scheme. The
remaining patients, except two, were covered by
private health insurance. The mean age at vari-
cella diagnosis in the (P) population was 4.2 years
(range 2 weeks – 34.9 years). The (A) population
was older, with a mean age of 10.9 years (range
3 weeks – 54.4 years), which reflects the fact that
general and internal practices take care mainly of
adult patients. However, the (P) population
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included a mother aged 34.9 years who was
treated together with her daughter in a paediatric
practice. Furthermore, some paediatricians have
special consulting hours for teenagers. This yields
a heavily right-skewed age distribution for the (P)
population. The population seen in general and
internal practices (A) is also right-skewed, with a
slight but characteristic peak between 18 and
40 years. Half of the (A) cases were aged between
3 weeks and 6.1 years.
Representative weighting of the (A) and (P)
populations yielded the overall age distribution of
diagnosed varicella cases in Germany shown in
Fig. 1. The mean age in the representative pop-
ulation was 7.4 years, with a median equal to the
mode of 5 years. The cumulative frequency graph
shows that 82.4% of the varicella patients were
aged <8 years, confirming that varicella is mainly
an infectious disease of children. However, the
characteristic peak of the (A) population was still
present, and 10% of diagnosed cases were aged
>12 years.
Table 1 gives an overview of the observed
varicella complications. In total, 92 complications
were reported by physicians. Sixteen of these
conditions were identified as coincident symp-
toms of other conditions unrelated to varicella
disease, or varicella symptoms which were severe,
but still normal during the course of the disease.
Therefore these conditions were not included in
the analysis of varicella complications. After cor-
rection, 76 complications were assessed as vari-
cella-related in the raw data, corresponding to
5.9% of patients in the (P) population and 5.4% of
patients in the (A) population, yielding a popula-
tion-weighted varicella complication rate of
(0.6 · 5.9%) + (0.4 · 5.4%) ¼ 5.7%.
As shown in Table 2, the most common com-
plications for children aged < 12 years were
bacterial superinfection, otitis media, pneumonia
and bronchitis. For the older age group, the most
common complications were bacterial superinfec-
tion and lower respiratory tract infections, with
many different diagnoses grouped together as
‘others’. No cases of otitis media or neurological
disorders were confirmed in this age group.
However, one case of fetal embryopathy asso-
ciated with varicella infection in a pregnant
woman was confirmed.
Most serious complications led to hospitalisa-
tion, with an average of 0.1 inpatient days ⁄diag-
nosed varicella case. Table 3 stratifies
hospitalisation rates according to the type of
complication and age group. For children, the
average number of inpatient treatment days was
2.6 on the intensive care unit and 1.3 on a regular
ward because of neurological varicella disorders,
as well as 0.7 intensive care days and 11.6 regular
ward days for varicella-induced pneumonia or
bronchitis. Observed hospitalisation in the adult
group was 9.1 days on average because of pneu-
monia. No intensive care cases were observed in
the adult population resulting from any compli-
cation. Only a few children were hospitalised
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Fig. 1. Age distribution of varicella cases in Germany.
Table 1. Complications associated with varicella infection
Complication
Absolute number of
cases in raw data
Average number of
days in hospital
Bacterial superinfection
(skin & scars)
35 0.7
Acute neurological disorder
(suspected or confirmed)
3 2.0
Pneumonia or bronchitis 12 3.5
Otitis media 13 0
Others 33
Conjunctivitis 7 0.1
Embryopathy 1 fetal malformation
Acute abdomen 1 12
Thrombocytopenia 2 4
Keratitis 1 0
Superinfected angina lacunaris 1 0
Total 76
The following conditions were documented, but not assessed, as complications of
varicella: mild eye signs, stomatitis, vulvitis, abdominal pain, ear complaints, fever,
intertrigo, balanitis, diaper dermatitis, atopic eczema, viral infection, enanthaema of
vagina and mouth, lymphadenitis, angina, febrile convulsion for other conditions,
herpes labialis, dysuria, suspected meningitis (not confirmed).
Table 2. Age-related complications associated with vari-
cella infection
Percentage frequency of varicella
complications (95% CI)
Aged £ 12 years Aged > 12 years
Bacterial superinfection of skin,
soft tissue and scars
2.5 (1.7–3.4) 1.9 (0.1–7.6)
Acute neurological disorder
(suspected or confirmed)
0.2 (0–0.5) no cases confirmed
Pneumonia or bronchitis 1.9 (0.5–1.6) 1.9 (0.1–7.6)
Otitis media 1.1 (0.7–1.8) no cases confirmed
Others 0.8 (0.4–1.4) 2.4 (0.6–9.9)
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because of superinfections of the skin. The average
inpatient period was 5.3 days on a regular ward.
No cases of hospitalisation with otitis media were
recorded.
Point sensitivity analysis of hospitalisation
rates with respect to the weighting ratio of
60 : 40 from 50 : 50 to 70 : 30 for the (P) and (A)
populations, respectively, resulted in a maximum
variation of ± 6% for neurological disorders. This
was smaller than half the range of the respective
95% CIs for any of the displayed complication
rates.
Table 4 summarises the main items accounting
for direct and indirect costs of varicella infection.
Of the diagnosed varicella cases, 16.3% were
considered to take a severe course by the treating
physician, while complications occurred in 5.7%
of the cases. Most of the indirect costs were
associated with certificates of sick leave. In 12% of
all cases, certificates of sick leave for parents
caring for their ill child were issued, with an
average length of 5.9 days. For a further 10% of
cases, an average of 7.3 days of work loss was
documented. For the diagnosed varicella cases
that obtained certificates of sick leave (22%), the
mean work absenteeism was 6.6 days. After
weighting for the real prevalence rates of the (A)
and (P) populations, this results in 1.3 days of
inability to work ⁄diagnosed varicella case. Of
these 1.3 days, 0.6 days are paid by health insur-
ance funds to parents caring for their sick child,
while 0.7 days ⁄diagnosed varicella case are paid
by employers to an employee unable to work
because of varicella disease. A more detailed
compilation of work losses according to diag-
nosed complications, stratified to children and
adults, is given in Table 5.
Applying the human capital approach, the
indirect costs of varicella were assessed for
Germany. With an annual incidence of 760 000
diagnosed cases in 1999 [1,16], and assumed costs
of 150.3 Euro ⁄ sick day, the indirect costs amount
to 150 million Euro ⁄ year. In the context of health
insurance, 70% of net wages are directly reim-
bursed in Germany to parents caring for their
child, amounting to c.50 million Euro ⁄ year related
to varicella.
D I S C U S S I O N
The present study provides estimates based on
diagnosed varicella cases. Data were collected
from across Germany, and the sampling was
representative of both rural and urban areas.
Taking into account the adjustment for the (A)
and (P) populations, representative estimates
were obtained for the age distribution, complica-
tions, sick benefits and demographic features of
diagnosed varicella cases. According to the sam-
ple size considerations, computed 95% confid-
ence intervals and point sensitivity ranges were
sufficiently small for rates down to 3% based on
the whole study population. This indicates satis-
fying accuracy for epidemiological conclusions
and further cost analyses.
Although vaccination for immunocompro-
mised patients is recommended in Germany, only
Table 3. Age-related complications leading to hospitalisa-
tion following varicella infection
Reason for hospitalisation
Percentage frequency
Aged £ 12 years Aged > 12 years
Bacterial superinfection of skin,
soft tissue and scars
2.1a no cases confirmed
Acute neurological disorder
(suspected or confirmed)
44a no cases confirmed
Pneumonia or bronchitis 41a 91a
Otitis media no cases confirmed no cases confirmed
Others 20a no cases confirmed
aNo confidence interval was calculated as only a few cases were observed.
Table 4. Overview of main items accounting for direct
and indirect costs of varicella infection
Item Study results (95% CI)
Severea disease course; percentage
of diagnosed varicella cases
16.3 (14.3–18.3)
Total varicella-related complications;
percentage of diagnosed cases
5.7 (4.5–6.9)
Hospitalisation period; days ⁄varicella case 0.1 (0.1–0.1) b
Contribution to indirect costs
Certificates of sick leave; days ⁄varicella case 1.3 (1.2–1.4)
Paid by health-insurance funds; days ⁄varicella case 0.6 (0.6–0.7)
Paid by the employer; days ⁄varicella case 0.7 (0.6–0.8)
aAs assessed by the treating physician.
bRounded to one digit.
Table 5. Average number of working days lost because of
varicella complications
Number of days lost (95% CI)
Child Adult
Uncomplicated course
(cases with no complication)
0.7 (0.6–0.8) 5.9 (3.7–6.8)
Bacterial superinfection of skin and scars 1 (0.2–1.9) 7.3
Acute neurological disorder
(suspected or confirmed)
0.7a no cases confirmed
Pneumonia or bronchitis 4.4 (1.7–7.2) 29.2 a
Otitis media 2 (0.5–3.5) no cases confirmed
Others 4 (1.8–6.1) 15.5 a
aNo confidence interval calculated as few cases were observed.
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one vaccinated patient was identified among 91
patients in this category. Other data (male:female
ratio and membership of private and statutory
health insurance schemes) were in accordance
with the birth cohort and the demographic situ-
ation of the whole German population [15]. The
relatively high number of children in the (A)
population (50% were aged between 3 weeks and
6.1 years) can be explained by the fact that the
rural population commonly consults a general
practitioner as family doctor, while paediatric
practices are concentrated in cities and urban
areas.
When the age distribution of diagnosed vari-
cella cases in the epidemiological study (Fig. 1)
was compared to the age distribution according to
seroprevalence data from a German seroepidemi-
ological survey [16,17], only slight differences
were observed in the age group of 2–15 years,
while almost no differences were found in the
other age groups. In the age group of 2–15 years,
the percentage of varicella cases in the seroprev-
alence study was slightly higher (2.5% – 9.8%)
than in the present study of diagnosed cases,
perhaps because of undiagnosed disease in some
patients. Beutels et al. [11] estimated the rate of
non-diagnosed varicella cases in Germany as
10%, based on a representative survey [18].
Estimates based on seroprevalences may be influ-
enced by these slight differences. The present
study focused only on diagnosed cases, since it
was only for such cases that complication rates,
number of physician visits and hospitalisation
data were available. Taking into account the
lower incidence rate of diagnosed vs. seropreva-
lence cases, both approaches are mathematically
equivalent.
Comparing the age distribution of diagnosed
cases in Germany with the situation in the UK
[19], it was observed that the shape of the
distribution functions coincided. Furthermore,
the characteristic peak was also present in both
countries, although the cases in Germany were
much younger (mean 7.4 years; median, mode
5 years) than in the UK (mean 14.2 years; median,
mode 9 years). This has to be seen in the light of a
possible previous age-shift in the UK [16]. The
mean age in an Italian paediatric population with
cases aged 0–14 years was comparable to the (P)
population in the present study, namely
4.5 ± 2 years in Italy [10] and 4.2 years in Ger-
many. The specified complication rate (3.5%) in
Italy was lower than the German rates (5.4% in
the (A) and 5.9% in the (P) population), probably
because bacterial superinfection of skin, soft
tissue and scars was not considered as a varicella
complication in Italy. The difference of 2.4%
between the Italian rate and the (P) population
rate in the present study fits very well with the
observed complication rate associated with bac-
terial superinfections for children (aged
£ 12 years) in Table 2. In this way the Italian data
validate and reinforce the overall complication
rate estimated in the present study.
The results of the study demonstrate that it is a
misconception to believe that varicella is uni-
formly a mild disease. The study also confirmed
findings from a study in the USA [20] that the
probability of severe complications, such as lower
respiratory tract infections, are increased in the
adult population, as indicated by the presence of
pneumonia and bronchitis in Table 2. These types
of severe complications, together with the neuro-
logical disorders seen in the child population,
require hospitalisation in most cases (Table 3).
Most of the direct costs associated with varicella
arise from complications and hospitalisations
generally paid by statutory health insurance
funds in Germany. Studies in Australia, Spain
and Italy [9,10,12] confirm the finding that direct
medical costs are only a small part of the total
costs of varicella infection.
The present study is the first to collect data
directly on work loss caused by varicella infection
in Germany. There is a special situation in
Germany, since 48% of the indirect costs of
varicella caused by loss of working days (i.e., 0.6
of 1.3 days in Table 4) are paid by the statutory
health insurance scheme. Considering only these
indirect costs, and taking into account the fact that
c.90% of varicella cases are diagnosed [18], it
seems that there are significant economic argu-
ments in favour of a universal vaccination policy,
from both the health budget and social perspec-
tives. However, more sophisticated approaches
are necessary to account for coverage rates and
potential age-shifts. An initial economic analysis,
based on the population model of Halloran et al.
[21], showed that universal varicella vaccination
could provide significant clinical and economic
benefits to German society [22]. A detailed eco-
nomic analysis [23] demonstrated that a routine
immunisation programme that succeeded in vac-
cinating all healthy children aged 1–1.5 years
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would be cost-effective from the viewpoint of
society, as well as third-party tax-payers.
A limitation resulting from the size of the study
population is the accuracy of estimating events
such as rare complications and hospitalisations
that occur at a frequency of < 3%. However,
according to sensitivity analyses [23], these rare
events do not contribute significantly to varicella
costs on a population level. For reasons of
completeness, the structured complication and
hospitalisation rates observed are shown in
Tables 2 and 3.
In conclusion, according to the efficacy results
[3,4] and epidemiological findings, the introduc-
tion of universal varicella vaccination in Germany
would provide significant clinical improvements
for patients and reduce hospital admissions. In
addition, significant economic benefits can be
expected for society as a whole, as well as health
insurance funds, because of the high impact of
indirect costs in Germany.
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